COMMUNIQUÉS West-GlobeNewswire
-
First Wave BioPharma Announces Completion of Business Combination with ImmunogenX, Adding Phase 3-Ready Latiglutenase to its Late-Stage GI-Focused Clinical Pipeline
14/03/2024 - 11:00 -
Aveanna Healthcare Holdings Announces Fourth Quarter 2023 Financial Results and 2024 Outlook
14/03/2024 - 11:30 -
Pluri Selected as CDMO by Remedy Cell for Cell-Derived Cell-Free Drug Manufacturing
14/03/2024 - 12:00 -
Tilray Medical Receives Approval for First Medical Cannabis Extract in Portugal
14/03/2024 - 12:00 -
Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors
14/03/2024 - 12:00 -
Microbix’s Clot-Buster Drug Project Advances
14/03/2024 - 12:00 -
AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update
14/03/2024 - 12:00 -
Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
14/03/2024 - 12:00 -
Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
14/03/2024 - 12:00 -
KidneyIntelX™ included in Final KDIGO 2024 Clinical Guideline for Chronic Kidney Disease (CKD)
14/03/2024 - 12:00 -
Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business Updates
14/03/2024 - 12:30 -
VitalHub Announces Q4 2023 Conference Call Date
14/03/2024 - 12:30 -
ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in a Panel Discussion Titled “Inflammation Illuminated,”at Benzinga’s Virtual Healthcare Summit 2024 on March 20, 2024
14/03/2024 - 12:57 -
60 Degrees Pharmaceuticals Announces Communication from the FDA of Intention to Respond to Tafenoquine-Babesiosis Trial Protocol Submission in April, 2024
14/03/2024 - 12:59 -
iSpecimen Reports Full Year 2023 Results
14/03/2024 - 13:00 -
Konica Minolta Healthcare Sponsors SPIE Best Student Paper Award
14/03/2024 - 13:00 -
MediWound to Report Fourth Quarter and Full Year 2023 Financial Results
14/03/2024 - 13:00 -
Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic Syndromes
14/03/2024 - 13:00 -
Achieve Life Sciences to Announce Fourth Quarter and Year-End 2023 Financial Results and Host Conference Call and Webcast on March 28, 2024
14/03/2024 - 13:00
Pages